A5111564401- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Microscopic Colitis
- Inflammatory Bowel Disease
- Liver Disease and Transplantation
- Pancreatitis Pathology and Treatment
- Diet, Metabolism, and Disease
- Systemic Lupus Erythematosus Research
- Eosinophilic Disorders and Syndromes
- Gastrointestinal disorders and treatments
- Advanced Biosensing Techniques and Applications
- Metabolism and Genetic Disorders
- Genetic factors in colorectal cancer
- HIV/AIDS drug development and treatment
- Gastrointestinal Tumor Research and Treatment
- Diagnosis and treatment of tuberculosis
- Lipid metabolism and disorders
- Lung Cancer Treatments and Mutations
- Gallbladder and Bile Duct Disorders
- Lymphatic Disorders and Treatments
- Tracheal and airway disorders
- Celiac Disease Research and Management
- Vasculitis and related conditions
- IL-33, ST2, and ILC Pathways
- Gastrointestinal Bleeding Diagnosis and Treatment
Saiseikai Utsunomiya hospital
2016-2025
Health Sciences University of Hokkaido
2002-2003
Non-alcoholic fatty liver disease (NAFLD) is frequently complicated by dyslipidemia and considered to be a hepatic manifestation of metabolic syndrome. Pemafibrate novel selective peroxisome proliferator-activated receptor-α modulator. There are no reports the clinical effects pemafibrate in patients with NAFLD. The aim this study determine effect on
The objectives of this real-world study were to determine 1-year persistence with vedolizumab in patients ulcerative colitis and evaluate factors contributing loss response. In multicenter, retrospective, observational chart review, moderately severely active who received ≥ 1 dose clinical practice at 16 tertiary hospitals Japan (from December 2018 through February 2020) enrolled. Persistence was 64.5% (n = 370); the median follow-up time 53.2 weeks. Discontinuation due response among...
Background and Aim: Controlling the hepatic inflammation of metabolic dysfunction-associated steatotic liver disease (MASLD) is important to prevent serious condition. Pemafibrate, a selective peroxisome proliferator-activated receptor-α modulator, has demonstrated effectiveness at standard dose (0.2 mg daily). The aim this study evaluate pemafibrate escalation from 0.2 0.4 daily in patients with MASLD who are refractory standard-dose therapy. Methods: This included had persistent elevation...
To optimize the long-term outcomes of patients with non-alcoholic fatty liver disease (NAFLD), therapy is important to prevent cirrhosis and hepatocellular carcinoma. Pemafibrate, a novel selective peroxisome proliferator-activated receptor-α modulator, promising therapeutic agent for NAFLD. However, only short-term clinical studies are currently available. The aim this study evaluate NAFLD treated pemafibrate.
Abstract Background and Aim: Although molecular mechanisms underlying ulcerative colitis (UC)‐associated neoplasms have been studied for years, understanding of these remains incomplete no good predictable marker development colonic in patients with UC has established. The aim this study was to assess if microsatellite instability (MSI) contributes the UC. Methods: We examined MSI chronic inflamed neoplastic mucosa patients. also obtained serial biopsied tissues retrospectively 2–12 years...
Aim This study aimed to evaluate the real‐world efficacy and safety of 12‐week sofosbuvir/velpatasvir (SOF/VEL) treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus (HCV) infection. Methods A total 72 Child–Pugh (CP) class B or were enrolled. We evaluated sustained virologic response at 12 weeks after end (SVR12), adverse events (AEs), changes in function. Results All participants had genotype 1 2 HCV At baseline, numbers CP 59 13, respectively. The overall...
ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Shinozaki S, Tahara T, Miura K, Kawarai Lefor A, Yamamoto H. Pemafibrate therapy for non-alcoholic fatty liver disease is more effective in lean patients than obese patients. Clinical and Experimental Hepatology - Manuscripts Accepted. 2022. doi:10.5114/ceh.2022.120099. APA Shinozaki, S., Tahara, T., Miura, K., Lefor, A., & Yamamoto, (2022). https://doi.org/10.5114/ceh.2022.120099 Chicago Satoshi, Toshiyuki...
The long-term outcomes of patients with non-alcoholic fatty liver disease (NAFLD) treated sodium-glucose cotransporter-2 inhibitors remain indeterminate. Empagliflozin improves hyperglycemia by increasing glucose excretion in the urine, and it reduces fat volume insulin resistance. aim this study is to assess effect empagliflozin therapy on hepatic inflammation, function fibrosis NAFLD. This a two-center retrospective observational including NAFLD complicated type 2 diabetes mellitus. We...
The treatment of refractory ascites due to cirrhosis is a clinical challenge for hepatologists. Tolvaptan, novel aquaporin modulator, was made available in Japan 2013 the patients with cirrhosis. Despite potential this drug, few reports are regarding its use. aim present study clarify efficacy tolvaptan and review outcomes treatment. Medical records were retrospectively reviewed 65 who treated daily 7.5 mg tolvaptan. median follow-up time, defined as period between starting last clinic visit...
Dermatomyositis (DM) is an autoimmune disease characterized by cutaneous Gottron papules, heliotrope rash, and proximal myopathy. It may also present as a paraneoplastic syndrome that can complicate variety of different cancers, such lung, cervical, breast cancer. However, the association with hepatocellular carcinoma (HCC) extremely rare. Moreover, to our knowledge, there are no previous reports colonic perforation following steroid pulse treatment for DM patient.A 61-year-old male...
Background: Both pemafibrate and sodium glucose cotransporter-2 (SGLT2) inhibitor can decrease serum transaminase levels in patients with non-alcoholic fatty liver disease (NAFLD) complicated dyslipidemia type 2 diabetes mellitus (T2DM), respectively. However, the effectiveness of combined therapy has been rarely reported. Methods: This is a two-center retrospective observational study. NAFLD T2DM treated for >1 year were included, whom prior treatment SGLT2 > 1 failed to normalize alanine...
Objective Regional disparities were observed in the outcomes of interferon (IFN)-based therapy for chronic hepatitis C virus (HCV) infection a Japanese nationwide study. However, whether or not these regional are direct-acting antiviral drugs, including sofosbuvir (SOF) plus ribavirin (RBV) therapy, remains unclear. Methods We conducted multicenter study to assess efficacy SOF RBV HCV genotype 2 Tochigi Prefecture and its vicinity, which IFN-based yielded low sustained virologic response...
Objective: Combination therapy with glecaprevir and pibrentasvir (G/P) has been shown to provide a sustained virologic response (SVR) rate of >97% in patients chronic hepatitis C virus (HCV) infection the first published real-world Japanese data. However, recently study showed that treatment was often discontinued ≥75 years old, resulting low SVR intention-to-treat (ITT) analysis. Thus, our aim evaluate data for G/P age, population density which is high "rural" regions. Patients Methods: We...
4076 Background: Intra-arterial cisplatin therapy for advanced hepatocellular carcinoma (HCC) has been reported a favorable tumor-shrinking effect and long-term survivals even in pts with highly HCC. The aim of this trial was to evaluate the efficacy safety ofsorafenib plus intra-arterial (SP) vs. sorafenib alone (S) Methods: In multicenter open-labeled randomized phase II trial, HCC no prior chemotherapy Child Pugh A or B7 were randomly assigned 2:1 receive SP (sorafenib: 800 mg, twice...
Although sofosbuvir plus ribavirin (SOF+RBV) treatment is highly effective for genotype 2 chronic hepatitis C infection, 3%-7% of patients failed to achieve a sustained virologic response (SVR). As the optimal combination direct-acting antivirals remains unclear, we conducted multicenter trial using 12-week Glecaprevir/Pibrentasvir (GLE/PIB) therapy who an SVR by SOF+RBV treatment. We encountered 13 patients; 9 men and 4 women. Of patients, 10 were 2a 3 2b. The rates rapid response, expected...
A 47-year-old man visited our hospital with the chief complaints of diarrhea, dysgeusia, alopecia and onychodystrophy. Endoscopic examinations revealed an edematous reddish mucosa many polypoid lesions in stomach colon. Cronkhite-Canada syndrome was diagnosed patient treated intravenous prednisolone. The symptoms improved gradually, however, remission not achieved. At one month after treatment, serum albumin level still persisted. We then decided to administer steroid pulse therapy. With...